Le Lézard
Classified in: Health, Science and technology, Business
Subjects: LIC, CXP

Mako Alliance Welcomes Circulogene and Expands Membership Across Five States


RALEIGH, N.C., March 5, 2024 /PRNewswire/ -- The Mako Alliance, a pioneering network of healthcare and biotechnology organizations dedicated to advancing medical research and patient care, is thrilled to announce the addition of Circulogene, a leading liquid biopsy testing company, to its esteemed roster of members. This strategic inclusion underscores the Alliance's commitment to integrating innovative diagnostic technologies that enhance cancer treatment and patient management.

Circulogene, known for its cutting-edge approach to liquid biopsy testing, provides comprehensive genomic profiling that aids in the detection and monitoring of cancer. By analyzing tiny amounts of DNA shed from tumors into the bloodstream, Circulogene's tests can identify mutations and alterations in cancer genes, offering valuable insights that guide treatment decisions. This non-invasive method represents a significant advancement in oncology, promising to improve outcomes for patients across the globe.

In addition to welcoming Circulogene, the Mako Alliance is proud to announce the expansion of its network with new members from Texas, Kentucky, Florida, New York, and California. While specifics of these new members are forthcoming, their inclusion is a testament to the Alliance's growing influence and its dedication to fostering collaborations that push the boundaries of medical research and healthcare services.

"The integration of Circulogene into the Mako Alliance marks a pivotal moment in our journey to revolutionize patient care through innovation," said a spokesperson for the Mako Alliance. "Their exceptional work in liquid biopsy testing is exactly the kind of innovation we aim to support. Furthermore, our expansion into five more states reflects our ongoing commitment to building a nationwide network that is at the forefront of healthcare advancements."

The Mako Alliance remains focused on its mission to accelerate the development and application of novel healthcare solutions by facilitating collaboration among its members. With the addition of Circulogene and new members from across the United States, the Alliance is set to enhance its impact on the healthcare landscape, driving forward the possibilities of personalized medicine and improved patient care.

For more information about the Mako Alliance and its members, please visit our website.

Contact: Mako Alliance Communications Email: [email protected] Website: https://www.makoalliance.com/

About the Mako Alliance: The Mako Alliance is a consortium of leading healthcare, biotechnology, and research organizations committed to improving patient outcomes through collaborative innovation. By uniting expertise and resources, the Alliance accelerates the development of new medical technologies and approaches to care, with a focus on oncology, genomics, and personalized medicine.

Mako Alliance
919-351-6256
[email protected]
https://www.makoalliance.com/

SOURCE Mako Alliance


These press releases may also interest you

at 06:00
Fennec Pharmaceuticals Inc. , a commercial stage specialty pharmaceutical company, today announced that Adrian Haigh has departed from his position as Fennec's Chief Operating Officer as of June 30, 2024. After nine years as an independent director,...

at 06:00
Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") , a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China, announced today that its board of directors...

at 06:00
BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that it will hold a mid-year corporate update to discuss recent positive developments in the NurOwn® program on...

at 05:26
Pope Francis hosted distinguished scientists and experts from various countries and disciplines at a private audience at the Apostolic Palace in Vatican City. The selected attendees were participants in the Three-day International Conference on...

at 05:05
LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, today announced the appointment of Staph Leavenworth Bakali as independent Chairman of its Board of Directors. Mr....

at 04:30
1 in 2 adults in the US have high blood pressure, and if you're over 55, the odds jump to 4 in 5. Given that heart attacks are the No.1 killer of men and women around the world, often precipitated by high blood...



News published on and distributed by: